64th ASH Annual Meeting and Exposition: 621. Lymphomas: Translational—Molecular and Genetic: Functional Genomics and Biology

Symposia: Lymphomas: Translational—Molecular and Genetic Oral and Poster Abstracts
Oral

Research, Fundamental Science, apoptosis, Translational Research, Lymphomas, non-Hodgkin lymphoma, CHIP, assays, genomics, bioinformatics, B Cell lymphoma, T Cell lymphoma, Diseases, immune mechanism, Therapies, immunology, aggressive lymphoma, Lymphoid Malignancies, metabolism, Biological Processes, Technology and Procedures, molecular biology, profiling, pathogenesis, molecular testing, omics technologies

388-390 (Ernest N. Morial Convention Center)

Moderators:

Roberto Chiarle, MD, Children's Hospital Boston and Wendy Béguelin, PhD, Weill Cornell Medicine

Disclosures:

No relevant conflicts of interest to declare.

2:45 PM

841

Mutations of the RNA Binding Protein hnRNP U Modulate MYC Expression in MYC-Driven Lymphomas

Qurat Ul Ain Qureshi, BSc¹^*, Krysta M. Coyle, PhD¹, Nicole Thomas¹, Brett Collinge²^*, Kostiantyn Dreval³^*, David W. Scott, PhD, MD, FRACP, FRCPA^2,4, Timothy E Audas, PhD¹^* and Ryan D. Morin^3,5

¹Department of Molecular Biology & Biochemistry, Simon Fraser University, Burnaby, BC, Canada
²Centre for Lymphoid Cancer, BC Cancer Research Centre, Vancouver, BC, Canada
³Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada
⁴Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada
⁵Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada

3:00 PM

842

Loss of Nr4a1 Causes an Elevated Expression of Co-Inhibitory Receptor:Ligand Axes and Results in a Diminished T Cell-Mediated Lymphoma Cell Killing in Aggressive Lymphoma

Katrin Pansy¹^*, Karoline Fechter²^*, Kerstin Wenzl, PhD³, Aditya Arra⁴^*, Joseph P. Novak³^*, Marta Szmyra²^*, Sandra Haingartner²^*, Alan G. Ramsay, BSc, MSc, PhD⁵, Anne J. Novak, PhD³, Hildegard T. Greinix, MD², Christine Beham-Schmid⁶^*, Peter Neumeister, MD¹^* and Alexander J.A. Deutsch¹^*

¹Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
²Division of Hematology, Medical University of Graz, Graz, Austria
³Division of Hematology, Mayo Clinic, Rochester, MN
⁴Clinic for Experimental Pedriatics, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany
⁵Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom
⁶Institute of Pathology, Medical University of Graz, Graz, Austria

3:15 PM

843

Co-Occurrence of TP53/PTEN and CCR4 genetic Alteration Deregulates T_H-Cell Differentiation and Drives T_H2-like Lymphomagenesis and T-Cell Signaling

Dylan T. Jochum, BS¹, Waseem G. Lone, Ph.D.¹^*, Alyssa C. Bouska, Ph.D.¹^*, Xuxiang Liu, PhD²^*, Jiayu Yu, PhD¹^*, Catalina Amador, MD³^*, Sunandini Sharma¹^*, Tyler A. Herek, PhD¹, Wing C. Chan, MD² and Javeed Iqbal, Ph.D.¹^*

¹Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
²Department of Pathology, City of Hope National Medical Center, Duarte, CA
³University of Miami Miller School of Medicine, Miami, FL

3:30 PM

844

TRAF3 Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma

Yu Y. Li, BS^1,2^*, Lauren C. Chong¹^*, Bruce W Woolcock¹^*, Adèle Telenius¹^*, Susana Ben-Neriah, MSc¹^*, Graham W Slack, MD, PhD^1,2^*, Vivian Lam³^*, Aixiang Jiang, MSc¹^*, Elena Viganò, PhD¹, Tomohiro Aoki, MD, PhD¹, Shannon Healy, PhD¹^*, Gerald Krystal, PhD³^*, Leandro Venturutti, PhD, MSc^1,2,3^*, David W. Scott, PhD, MD, FRACP, FRCPA¹ and Christian Steidl, MD^1,2

¹Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada
²Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
³Terry Fox Laboratory, BC Cancer, Vancouver, BC, Canada

3:45 PM

845

CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

Salomé Decombis¹^*, Celine Bellanger¹^*, Yannick LE Bris, PhD, PharmD^1,2^*, Delphine Boulet, PhD¹^*, Jane Jardine, PhD¹^*, Christelle Dousset¹^*, Audrey Ménard²^*, Charlotte Kervoelen, PhD³^*, Elise Douillard¹^*, Philippe Moreau, MD^1,4^*, Stephane Minvielle, PhD¹^*, Agnes Moreau-Aubry, PhD¹^*, Benoit Tessoulin, MD^1,5^*, Nicolas Bidère, PhD¹^*, Steven Le Gouill, MD, PhD⁶, Catherine Pellat-Deceunynck, PhD¹ and David Chiron, PhD¹^*

¹CRCI2NA, Integrated Research Center in Immunology and Oncology, Nantes University, Nantes, France
²Department of Biological Hematology, CHU Nantes, Nantes, France
³Therassay (Onco-Hemato) Core Facility, Nantes Université, Capacités, Nantes, France
⁴Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
⁵Hematology Department, Nantes University Hospital, Nantes, France
⁶Institut Curie, Paris, Paris, France

4:00 PM

846

Alpha-Ketoglutarate Suppresses MYC and mTORC1 and Displays Anti-Lymphoma Activity

Carine Jaafar, PhD¹^*, Purushoth Ethiraj, PhD¹^*, Zhijun Qiu, PhD¹^*, An-Ping Lin¹^* and Ricardo Aguiar, MD, PhD²

¹University of Texas Health Science Center, San Antonio, TX
²University of Texas Health Sci. Ctr., San Antonio, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

621.O3.6 621. Lymphomas: Translational—Molecular and Genetic: Functional Genomics and Biology